Goldman Sachs Maintains Neutral on APA, Lowers Price Target to $41
Goldman Sachs maintains APA (NASDAQ:APA) with a Neutral and lowers the price target from $52 to $41.
Needham Initiates Coverage On Definitive Healthcare with Buy Rating, Announces Price Target of $30
Needham analyst Ryan MacDonald initiates coverage on Definitive Healthcare (NASDAQ:DH) with a Buy rating and announces Price Target of $30.
Oppenheimer Initiates Coverage On Portman Ridge Finance with Perform Rating, Announces Price Target of $26
Oppenheimer analyst Mitchel Penn initiates coverage on Portman Ridge Finance (NASDAQ:PTMN) with a Perform rating and announces Price Target of $26.
JP Morgan Initiates Coverage On Avid Technology with Overweight Rating, Announces Price Target of $33
JP Morgan analyst Paul Chung initiates coverage on Avid Technology (NASDAQ:AVID) with a Overweight rating and announces Price Target of $33.
SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $64
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $66 to $64.
Raymond James Maintains Outperform on CME Group, Lowers Price Target to $235
Raymond James analyst Patrick O'Shaughnessy maintains CME Group (NASDAQ:CME) with a Outperform and lowers the price target from $254 to $235.
Why ZIM Integrated Shipping Shares Are Diving Today
BofA analyst Muneeba Kayani downgraded ZIM Integrated Shipping Services Ltd (NYSE:ZIM) to Underperform from Buy and lowered the price target to $40 (a…
EF Hutton Maintains Buy on Aspen Aerogels, Lowers Price Target to $18
EF Hutton analyst Chip Moore maintains Aspen Aerogels (NYSE:ASPN) with a Buy and lowers the price target from $48 to $18.
Mizuho Slashes Price Targets Of Mastercard, Visa Out Of Precaution – Read Why
Mizuho analyst Dan Dolev maintained Mastercard Inc (NYSE:MA) with a Buy, cut the price target from $435 to $375, maintained Visa Inc (NYSE:V) with a…
Here’s Why Accolade Shares Are Trading Higher Today
Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted…